{"id":59659,"date":"2026-06-04T22:44:26","date_gmt":"2026-06-04T13:44:26","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4893\/"},"modified":"2026-09-13T16:10:06","modified_gmt":"2026-09-13T07:10:06","slug":"company-4893","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4893\/","title":{"rendered":"NOILE-IMMUNE BIOTECH INC"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4893","DATE":"2026-01-09","longName":"Noile-Immune Biotech Inc.","company_name_ja":"","fullTimeEmployees":23,"address":"","phone":"","website":"https:\/\/www.noile-immune.com","industry":"Biotechnology","sector":"Healthcare","regularMarketPrice":146,"financialCurrency":"","marketCap":6322,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":-18.329999999999998,"epsForward":0,"bookValue":0,"totalRevenue":5000000,"OperatingIncome":-797254000,"operatingMargins":-15945.08,"NetIncome":-793536000,"profitMargins":-15870.719999999999,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":-20.18,"recommendationMean":0,"recommendationKey":"none","targetMeanPrice":440,"numberOfAnalystOpinions":1,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-09-01T05:01:30.647822\", \"ticker\": \"4893\", \"ticker_full\": \"4893.T\", \"company_name\": \"NOILE-IMMUNE BIOTECH INC\", \"analyst_recommendations\": {\"has_data\": true, \"recommendation_key\": \"none\", \"recommendation_mean\": null, \"total_analysts\": 1, \"strong_buy\": null, \"buy\": null, \"hold\": null, \"sell\": null, \"strong_sell\": null}, \"target_prices\": {\"has_data\": true, \"current\": 149.0, \"high\": 440.0, \"low\": 440.0, \"mean\": 440.0, \"median\": 440.0}, \"earnings_dates\": {\"has_data\": true, \"next_earnings\": null, \"future_count\": 0, \"past_earnings\": [{\"date\": \"2026-08-12\", \"eps_estimate\": -5.51, \"eps_actual\": -5.05, \"surprise_pct\": 8.35}, {\"date\": \"2026-05-13\", \"eps_estimate\": -5.05, \"eps_actual\": -3.54, \"surprise_pct\": 29.9}, {\"date\": \"2026-02-12\", \"eps_estimate\": -5.42, \"eps_actual\": -4.36, \"surprise_pct\": 19.56}, {\"date\": \"2025-11-12\", \"eps_estimate\": -11.04, \"eps_actual\": -4.46, \"surprise_pct\": 59.6}, {\"date\": \"2025-08-07\", \"eps_estimate\": -5.7, \"eps_actual\": -3.96, \"surprise_pct\": 30.53}]}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 56.92, \"institution_pct\": 3.11, \"major_holders\": [{\"label\": \"\", \"value\": 56.92}, {\"label\": \"\", \"value\": 3.11}, {\"label\": \"\", \"value\": 7.22}, {\"label\": \"\", \"value\": 1.0}], \"institutional_holders\": [], \"mutualfund_holders\": []}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company's product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, a next-generation CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-09-13T04:25:01.031013\", \"ticker\": \"4893\", \"ticker_full\": \"4893.T\", \"company_name\": \"NOILE-IMMUNE BIOTECH INC\", \"company_info\": {\"name_en\": \"NOILE-IMMUNE BIOTECH INC\", \"long_name\": \"Noile-Immune Biotech Inc.\", \"sector\": \"Healthcare\", \"industry\": \"Biotechnology\", \"website\": \"https:\/\/www.noile-immune.com\", \"employees\": 23, \"country\": \"Japan\", \"city\": \"Minato\", \"address\": \"T&G Hamamatsucho Building\", \"description\": \"Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company's product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, a next-generation CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 142.8, \"deviation\": -2.66, \"trend\": \"down\"}, \"ma_25\": {\"ma_value\": 144.32, \"deviation\": -3.69, \"trend\": \"down\"}, \"ma_75\": {\"ma_value\": 134.45, \"deviation\": 3.38, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 144.32, \"deviation\": -3.69, \"trend\": \"down\"}}, \"financials\": {\"years\": [{\"year\": 2025, \"revenue\": 5000000.0, \"revenue_fmt\": \"\u00a55.0M\", \"gross_profit\": 5000000.0, \"gross_profit_fmt\": \"\u00a55.0M\", \"operating_income\": -797254000.0, \"operating_income_fmt\": \"-\u00a58\u5104\", \"ebit\": -797254000.0, \"ebit_fmt\": \"-\u00a58\u5104\", \"net_income\": -793536000.0, \"net_income_fmt\": \"-\u00a58\u5104\", \"eps\": -18.33, \"operating_margin\": -15945.08, \"total_assets\": 4011579000.0, \"total_assets_fmt\": \"\u00a540\u5104\", \"total_equity\": 3931940000.0, \"total_equity_fmt\": \"\u00a539\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 3918321000.0, \"total_cash_fmt\": \"\u00a539\u5104\", \"equity_ratio\": 98.01, \"de_ratio\": 0.0, \"current_ratio\": 53.54, \"operating_cf\": -752219000.0, \"operating_cf_fmt\": \"-\u00a58\u5104\", \"investing_cf\": -378000.0, \"investing_cf_fmt\": \"-\u00a5378,000\", \"financing_cf\": -20000.0, \"financing_cf_fmt\": \"-\u00a520,000\", \"free_cf\": -752219000.0, \"free_cf_fmt\": \"-\u00a58\u5104\", \"net_margin\": -15870.72, \"roe\": -20.18, \"roa\": -19.78}, {\"year\": 2024, \"revenue\": 7587000.0, \"revenue_fmt\": \"\u00a57.6M\", \"gross_profit\": 7392000.0, \"gross_profit_fmt\": \"\u00a57.4M\", \"operating_income\": -1069182000.0, \"operating_income_fmt\": \"-\u00a511\u5104\", \"ebit\": -1069182000.0, \"ebit_fmt\": \"-\u00a511\u5104\", \"net_income\": -964455000.0, \"net_income_fmt\": \"-\u00a510\u5104\", \"eps\": -22.28, \"operating_margin\": -14092.29, \"total_assets\": 4800172000.0, \"total_assets_fmt\": \"\u00a548\u5104\", \"total_equity\": 4725497000.0, \"total_equity_fmt\": \"\u00a547\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 4670939000.0, \"total_cash_fmt\": \"\u00a547\u5104\", \"equity_ratio\": 98.44, \"de_ratio\": 0.0, \"current_ratio\": 68.77, \"operating_cf\": -887809000.0, \"operating_cf_fmt\": \"-\u00a59\u5104\", \"investing_cf\": 557000.0, \"investing_cf_fmt\": \"\u00a5557,000\", \"financing_cf\": 2500000.0, \"financing_cf_fmt\": \"\u00a52.5M\", \"free_cf\": -887809000.0, \"free_cf_fmt\": \"-\u00a59\u5104\", \"net_margin\": -12711.94, \"roe\": -20.41, \"roa\": -20.09}, {\"year\": 2023, \"revenue\": 316818000.0, \"revenue_fmt\": \"\u00a53\u5104\", \"gross_profit\": 314561000.0, \"gross_profit_fmt\": \"\u00a53\u5104\", \"operating_income\": -775391000.0, \"operating_income_fmt\": \"-\u00a58\u5104\", \"ebit\": -775391000.0, \"ebit_fmt\": \"-\u00a58\u5104\", \"net_income\": -1130014000.0, \"net_income_fmt\": \"-\u00a511\u5104\", \"eps\": -27.25, \"operating_margin\": -244.74, \"total_assets\": 5778946000.0, \"total_assets_fmt\": \"\u00a558\u5104\", \"total_equity\": 5687452000.0, \"total_equity_fmt\": \"\u00a557\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 5555691000.0, \"total_cash_fmt\": \"\u00a556\u5104\", \"equity_ratio\": 98.42, \"de_ratio\": 0.0, \"current_ratio\": 66.28, \"operating_cf\": -873076000.0, \"operating_cf_fmt\": \"-\u00a59\u5104\", \"investing_cf\": -5316000.0, \"investing_cf_fmt\": \"-\u00a55.3M\", \"financing_cf\": 1913086000.0, \"financing_cf_fmt\": \"\u00a519\u5104\", \"free_cf\": -873076000.0, \"free_cf_fmt\": \"-\u00a59\u5104\", \"net_margin\": -356.68, \"roe\": -19.87, \"roa\": -19.55}, {\"year\": 2022, \"revenue\": 625783000.0, \"revenue_fmt\": \"\u00a56\u5104\", \"gross_profit\": 618706000.0, \"gross_profit_fmt\": \"\u00a56\u5104\", \"operating_income\": -106345000.0, \"operating_income_fmt\": \"-\u00a51\u5104\", \"ebit\": -106345000.0, \"ebit_fmt\": \"-\u00a51\u5104\", \"net_income\": -386622000.0, \"net_income_fmt\": \"-\u00a54\u5104\", \"eps\": -9.87, \"operating_margin\": -16.99, \"total_assets\": 4641032000.0, \"total_assets_fmt\": \"\u00a546\u5104\", \"total_equity\": 4300617000.0, \"total_equity_fmt\": \"\u00a543\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 4520997000.0, \"total_cash_fmt\": \"\u00a545\u5104\", \"equity_ratio\": 92.67, \"de_ratio\": 0.0, \"current_ratio\": 13.68, \"operating_cf\": -107176000.0, \"operating_cf_fmt\": \"-\u00a51\u5104\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 487615000.0, \"financing_cf_fmt\": \"\u00a55\u5104\", \"free_cf\": -107176000.0, \"free_cf_fmt\": \"-\u00a51\u5104\", \"net_margin\": -61.78, \"roe\": -8.99, \"roa\": -8.33}, {\"year\": 2021, \"revenue\": 0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": 0, \"operating_income_fmt\": \"N\/A\", \"ebit\": 0, \"ebit_fmt\": \"N\/A\", \"net_income\": 0, \"net_income_fmt\": \"N\/A\", \"eps\": 0, \"operating_margin\": 0, \"total_assets\": 0, \"total_assets_fmt\": \"N\/A\", \"total_equity\": 0, \"total_equity_fmt\": \"N\/A\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 0, \"total_cash_fmt\": \"N\/A\", \"equity_ratio\": 0, \"de_ratio\": 0, \"current_ratio\": 0, \"operating_cf\": 0, \"operating_cf_fmt\": \"N\/A\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 0, \"financing_cf_fmt\": \"N\/A\", \"free_cf\": 0, \"free_cf_fmt\": \"N\/A\", \"net_margin\": 0, \"roe\": 0, \"roa\": 0}], \"has_data\": true}, \"dividends\": {\"history\": [], \"has_data\": false}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-59659","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NOILE-IMMUNE BIOTECH INC - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4893\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4893\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4893\/\",\"name\":\"NOILE-IMMUNE BIOTECH INC - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-04T13:44:26+00:00\",\"dateModified\":\"2026-09-13T07:10:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4893\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4893\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4893\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NOILE-IMMUNE BIOTECH INC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NOILE-IMMUNE BIOTECH INC - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4893\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4893\/","url":"https:\/\/japanir.jp\/en\/company\/company-4893\/","name":"NOILE-IMMUNE BIOTECH INC - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-04T13:44:26+00:00","dateModified":"2026-09-13T07:10:06+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4893\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4893\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4893\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"NOILE-IMMUNE BIOTECH INC"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/59659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=59659"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=59659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}